CRISPR is one of the most revolutionary technologies of the modern era, and now it's being used to bring back long-lost genes from our past.

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...

The Food and Drug Administration (FDA) approved the gene therapy Casgevy in December, which uses CRISPR/Cas9 genome editing technology to treat sickle-cell disease (SCD) in patients twelve years and ...

Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine Newly published research offers a novel technique to ...

The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments that ...

At the height of the COVID-19 pandemic in 2020, Marvin Collins ’22, a bioengineering student, was balancing their Stanford classes from home in Alabama while also helping bioengineering professor ...

Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting ...

CRISPR is a gene-editing tool that acts like “molecular scissors,” but using it on cancer is complex. The technology’s biggest impact so far is in research labs, helping scientists understand how ...

TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while ...

To investigate how Cas9 gene editing affected T cells, the researchers targeted the first exon of the TRAC locus, which encodes the T cell receptor on chromosome 14. As expected, DNA sequencing ...